Current and historical daily PE Ratio for Moleculin Biotech Inc (
) from 2016 to May 13 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Moleculin Biotech stock (MBRX) PE ratio as of May 13 2024 is 0.
More Details
Moleculin Biotech Inc (MBRX) PE Ratio (TTM) Chart
Moleculin Biotech Inc (MBRX) PE Ratio (TTM) Historical Data
View and export this data going back to 2016. Start your Free Trial
Total 1227
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Moleculin Biotech PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-13 | At Loss | 2024-03-08 | At Loss |
| 2024-05-10 | At Loss | 2024-03-07 | At Loss |
| 2024-05-09 | At Loss | 2024-03-06 | At Loss |
| 2024-05-08 | At Loss | 2024-03-05 | At Loss |
| 2024-05-07 | At Loss | 2024-03-04 | At Loss |
| 2024-05-06 | At Loss | 2024-03-01 | At Loss |
| 2024-05-03 | At Loss | 2024-02-29 | At Loss |
| 2024-05-02 | At Loss | 2024-02-28 | At Loss |
| 2024-05-01 | At Loss | 2024-02-27 | At Loss |
| 2024-04-30 | At Loss | 2024-02-26 | At Loss |
| 2024-04-29 | At Loss | 2024-02-23 | At Loss |
| 2024-04-26 | At Loss | 2024-02-22 | At Loss |
| 2024-04-25 | At Loss | 2024-02-21 | At Loss |
| 2024-04-24 | At Loss | 2024-02-20 | At Loss |
| 2024-04-23 | At Loss | 2024-02-16 | At Loss |
| 2024-04-22 | At Loss | 2024-02-15 | At Loss |
| 2024-04-19 | At Loss | 2024-02-14 | At Loss |
| 2024-04-18 | At Loss | 2024-02-13 | At Loss |
| 2024-04-17 | At Loss | 2024-02-12 | At Loss |
| 2024-04-16 | At Loss | 2024-02-09 | At Loss |
| 2024-04-15 | At Loss | 2024-02-08 | At Loss |
| 2024-04-12 | At Loss | 2024-02-07 | At Loss |
| 2024-04-11 | At Loss | 2024-02-06 | At Loss |
| 2024-04-10 | At Loss | 2024-02-05 | At Loss |
| 2024-04-09 | At Loss | 2024-02-02 | At Loss |
| 2024-04-08 | At Loss | 2024-02-01 | At Loss |
| 2024-04-05 | At Loss | 2024-01-31 | At Loss |
| 2024-04-04 | At Loss | 2024-01-30 | At Loss |
| 2024-04-03 | At Loss | 2024-01-29 | At Loss |
| 2024-04-02 | At Loss | 2024-01-26 | At Loss |
| 2024-04-01 | At Loss | 2024-01-25 | At Loss |
| 2024-03-28 | At Loss | 2024-01-24 | At Loss |
| 2024-03-27 | At Loss | 2024-01-23 | At Loss |
| 2024-03-26 | At Loss | 2024-01-22 | At Loss |
| 2024-03-25 | At Loss | 2024-01-19 | At Loss |
| 2024-03-22 | At Loss | 2024-01-18 | At Loss |
| 2024-03-21 | At Loss | 2024-01-17 | At Loss |
| 2024-03-20 | At Loss | 2024-01-16 | At Loss |
| 2024-03-19 | At Loss | 2024-01-12 | At Loss |
| 2024-03-18 | At Loss | 2024-01-11 | At Loss |
| 2024-03-15 | At Loss | 2024-01-10 | At Loss |
| 2024-03-14 | At Loss | 2024-01-09 | At Loss |
| 2024-03-13 | At Loss | 2024-01-08 | At Loss |
| 2024-03-12 | At Loss | 2024-01-05 | At Loss |
| 2024-03-11 | At Loss | 2024-01-04 | At Loss |
Moleculin Biotech Inc (MBRX) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Moleculin Biotech Inc
NAICS : 325412
SIC : 2834
ISIN : US60855D1019
Description
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers